News
An ambitious wave of Chinese entrepreneurs is changing the definition of Chinese private equity investment, as the market ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2025 and updated its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback